Pancreatic Neuroendocrine Tumours

  • Paul R. V. JohnsonEmail author


Pancreatic tumours are rare in children overall. Of those presenting in the under 20-year-old age-group, 30% are reported to be pancreatic neuroendocrine tumours (PaNETs), although due to their frequently asymptomatic and indolent nature, PaNETs are probably under-diagnosed in children. Pa NETs are the second commonest manifestation of MEN1, occurring in up to 80% of patients. Although encountered infrequently, PaNETs can present significant diagnostic and treatment challenges for the paediatric endocrinologist and paediatric surgeon. This chapter aims to provide an overview of PaNETs and emphasises the importance of a multi-disciplinary approach to ensure optimal care for children with these rare endocrine tumours.


Pancreatic tumours MEN 1 tumours Paediatric pancreatic tumours Endocrine tumours in children Multiple endocrine neoplasia type 1 



The author would like to acknowledge the contribution of Gerard Walls to this chapter.


  1. 1.
    Jaksic T, Yaman M, Thorner P, Wesson DK, Filler RM, Shandling B. A 20-year review of pediatric pancreatic tumors. J Pediatr Surg. 1992;27(10):1315–7.CrossRefPubMedGoogle Scholar
  2. 2.
    Vane DW, Grosfeld JL, West KW, Rescorla FJ. Pancreatic disorders in infancy and childhood: experience with 92 cases. J Pediatr Surg. 1989;24(8):771–6.CrossRefPubMedGoogle Scholar
  3. 3.
    Newey PJ, Jeyabalan J, Walls GV, Christie PT, Gleeson FV, Gould S, et al. Asymptomatic children with multiple endocrine neoplasia type 1 mutations may harbor nonfunctioning pancreatic neuroendocrine tumors. J Clin Endocrinol Metab. 2009;94(10):3640–6.CrossRefPubMedGoogle Scholar
  4. 4.
    Trump D, Farren B, Wooding C, Pang JT, Besser GM, Buchanan KD, et al. Clinical studies of multiple endocrine neoplasia type 1 (MEN1). QJM. 1996;89(9):653–69.CrossRefPubMedGoogle Scholar
  5. 5.
    Jensen RT, Berna MJ, Bingham DB, et al. Inherited pancreatic endocrine tumour syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies. Cancer. 2008;113(7 Suppl):1807–43.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Lodish MB, Stratakis CA. Endocrine tumours in neurofibromatosis type 1, tuberous sclerosis, and related syndromes. Best Pract Res Clin Endocrinol Metab. 2010;24(3):439–49.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Rindi G, Klöppel G, Alhman H, et al. All other Frascati Consensus Conference participants.; European Neuroendocrine Tumor Society (ENETS). TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006;449(4):395–401.Google Scholar
  8. 8.
    Sobin LH, Gospodarowicz MK, Wittekind C, editors. TNM classification of malignant tumours. Oxford: Wiley-Blackwell; 2009.Google Scholar
  9. 9.
    Jiao Y, Shi C, Edil BH, et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumours. Science. 2011;331(6021):1199–203.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Berretta M. Biomarkers in neuroendocrine tumors. Front Biosci. 2010;S2:332.CrossRefGoogle Scholar
  11. 11.
    Ferolla P, Faggiano A, Mansueto G, et al. The biological characterization of neuroendocrine tumors: the role of neuroendocrine markers. J Endo Invest. 2008;31(3):277–86.CrossRefGoogle Scholar
  12. 12.
    Kulke MH, Mayer RJ. Carcinoid Tumors. N Engl J Med. 1999;340:858–68.CrossRefPubMedGoogle Scholar
  13. 13.
    Kloppel G. Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer. 2011;18:S1–16.CrossRefPubMedGoogle Scholar
  14. 14.
    Klimstra DS, Modlin IR, Coppola D, et al. The pathologic classification of neuroendocrine tumors. Pancreas. 2010;39(6):707–12.CrossRefPubMedGoogle Scholar
  15. 15.
    Bosman FT, Carneiro F, Hruban RH, et al. WHO classification of tumours of the digestive system. Lyon: IARC; 2010.Google Scholar
  16. 16.
    Sokmensuer C, Gedikoglu G, Uzunalimoglu B. Importance of proliferation markers in gastrointestinal carcinoid tumours: a clinicopathologic study. Hepatogastroenterology. 2001;48:720–3.PubMedGoogle Scholar
  17. 17.
    Rindi G, Falconi M, Klersy C, et al. TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study. J Natl Cancer Inst. 2012;104(10):764–77.CrossRefPubMedGoogle Scholar
  18. 18.
    Falconi M, Eriksson B, Kaltas G, Bartsch DK, Capdevilla J, Caplin M, Kos-Kudla B. ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors. Neuroendocrinology. 2016;103(2):153–71.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Kimura W, Kurodan A, Morioka Y. Clinical pathology of endocrine tumors of the pancreas. Analysis of autopsy cases. Dig Dis Sci. 1991;36(7):933–42.CrossRefPubMedGoogle Scholar
  20. 20.
    Zollinger RM, Ellison EH. Primary peptic ulcerations of the jejunum associated with islet cell tumors of the pancreas. 1955. CA Cancer J Clin. 1989;39(4):231–4.Google Scholar
  21. 21.
    Pipeleers-Marichal M, Somers G, Willems G, Foulis A, Imrie C, Bishop AE, et al. Gastrinomas in the duodenums of patients with multiple endocrine neoplasia type 1 and the Zollinger-Ellison syndrome. N Engl J Med. 1990;322(11):723–7.CrossRefPubMedGoogle Scholar
  22. 22.
    Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab. 2001;86(12):5658–71.CrossRefPubMedGoogle Scholar
  23. 23.
    Levy-Bohbot N, Merle C, Goudet P, Delemer B, Calender A, Jolly D, et al. Prevalence, characteristics and prognosis of MEN 1-associated glucagonomas, VIPomas, and somatostatinomas: study from the GTE (Groupe des Tumeurs Endocrines) registry. Gastroenterol Clin Biol. 2004;28(11):1075–81.CrossRefPubMedGoogle Scholar
  24. 24.
    Akerström G, Hellman P. Surgical aspects of neuroendocrine tumours. Eur J Cancer. 2009;45(Suppl 1):237–50.CrossRefPubMedGoogle Scholar
  25. 25.
    Ramage JK, Ahmed A, Ardill J, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumors (NETs). Gut. 2012;61:6–32.CrossRefPubMedGoogle Scholar
  26. 26.
    Ardil JE. Circulating markers for endocrine tumours of the gastroenteropancreatic tract. Ann Clin Biochem. 2008;45:539–59.CrossRefGoogle Scholar
  27. 27.
    Eriksson B, Annibale B, Bajetta E, Mitry E, Pavel M, Platania M, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: chemotherapy in patients with neuroendocrine tumors. Neuroendocrinology. 2009;90(2):214–9.CrossRefPubMedGoogle Scholar
  28. 28.
    Maroun J, Koch W, Kvols L, et al. Guidelines for the diagnosis and management of carcinoid tumours. Part 1: the gastrointestinal tract. A statement from a Canadian national carcinoid expert group. Curr Oncol. 2006;13(2):67–76.PubMedPubMedCentralGoogle Scholar
  29. 29.
    Thakker RV, Newey PJ, Walls GV, Bilezikian J, Dralle H, Ebeling PR, et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab. 2012;97(9):2990–3011.CrossRefPubMedGoogle Scholar
  30. 30.
    Oberg K, Ferone D, Kaltsas G, Knigge UP, Taal B, Plockinger U. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: biotherapy. Neuroendocrinology. 2009;90(2):209–13.CrossRefPubMedGoogle Scholar
  31. 31.
    Kwekkeboom D, Rindi G, Kloppel G, Reed N, Klanmanesh R, Jensen RT. Vienna consensus conference particpants. ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors. Neuroendocrinology. 2016;103(2):153–71.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):501–13.CrossRefPubMedGoogle Scholar
  33. 33.
    Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):514–23.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371(3):224–33.CrossRefPubMedGoogle Scholar
  35. 35.
    Berna MJ, Annibale B, Marignani M, Luong TV, Corleto V, Pace A, et al. A prospective study of gastric carcinoids and enterochromaffin-like cell changes in multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: identification of risk factors. J Clin Endocrinol Metab. 2008;93(5):1582–91.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Allan B, David J, Perez E, et al. Malignant neuroendocrine tumors: incidence and outcomes in paediatric patients. Eur J Paed Surg. 2013;23:394–9.CrossRefGoogle Scholar
  37. 37.
    Pape UF, Jann H, Muller-Nordhorn J, et al. Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer. 2008;113:256–65.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany 2018

Authors and Affiliations

  1. 1.Academic Pediatric Surgery Unit, Nuffield Department of Surgical Sciences, John Radcliffe HospitalUniversity of Oxford and Oxford Islet Transplant ProgrammeOxfordUK

Personalised recommendations